$USAQ “Today’s announcement is further evidence of our continued progress and momentum as we expand our independent medical provider practice network. The growing interest in AllergiEnd®’s allergy diagnostic services and allergen immunotherapy products reflects the attractiveness of our value-based tools to proactively address chronic disease, provide preventive care as well as enable the broad market of general practitioner physicians to broaden their practices and revenue base,” said Troy Grogan, CEO of USA Equities Corp.

“Our new distributor relationship announced today has a significant growing national physician customer base and footprint which offers us a strong platform from which to increase our base of clients and over time potentially launch additional products. We are entering the second half of fiscal 2021 very well positioned and highly energized to grow our client and recurring revenue base, continue to increase our industry visibility and progress our work to expand our product portfolio as we further execute on our growth strategy,” concluded Grogan.

https://www.wsj.com/articles/usa-equities-cor...30?tesla=y